FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Endre Mikus

Research Profile

Chemicals & Drugs

Living Beings

Disorders

Physiology

Binding, Competitive

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Endre Mikus; Judit Szeredi; Géza Tímári; Péter Aranyi; Kinga Boer; Michel Finet; Anne-Marie Galzin
Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models.
Endre Mikus; Tibor Szabó; Judit Szeredi; Géza Timári; Katalin Urbán-Szabó; Péter Arányi; Sándor Bátori; Kinga Boér; Michel Finet; Katalin Gerber; Zoltan Kapui; Anne-Marie Galzin
Interaction of SSR161421, a novel specific adenosine A(3) receptor antagonist with adenosine A(3) receptor agonists both in vitro and in vivo.
Zoltan Kapui; Marton Varga; Katalin Urban-Szabo; Endre Mikus; Tibor Szabo; Judit Szeredi; Sandor Batori; Olivier Finance; Peter Aranyi
Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Endre Mikus (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Endre Mikus; Judit Szeredi; Géza Tímári; Péter Aranyi; Kinga Boer; Michel Finet; Anne-Marie Galzin
Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models.
European journal of pharmacology 2013;699(1-3):172-9.
2013: Endre Mikus; Tibor Szabó; Judit Szeredi; Géza Timári; Katalin Urbán-Szabó; Péter Arányi; Sándor Bátori; Kinga Boér; Michel Finet; Katalin Gerber; Zoltan Kapui; Anne-Marie Galzin
Interaction of SSR161421, a novel specific adenosine A(3) receptor antagonist with adenosine A(3) receptor agonists both in vitro and in vivo.
European journal of pharmacology 2013;699(1-3):62-6.
2003: Zoltan Kapui; Marton Varga; Katalin Urban-Szabo; Endre Mikus; Tibor Szabo; Judit Szeredi; Sandor Batori; Olivier Finance; Peter Aranyi
Biochemical and pharmacological characterization of 2-(9-(2-piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a novel, orally active elastase inhibitor.
The Journal of pharmacology and experimental therapeutics 2003;305(2):451-9.
2003: Márton Varga; Zoltan Kapui; Sándor Bátori; Lajos T Nagy; Lelle Vasvári-Debreczy; Endre Mikus; Katalin Urbán-Szabó; Péter Arányi
A novel orally active inhibitor of HLE.
European journal of medicinal chemistry 2003;38(4):421-5.
1999: Zoltan Kapui; P Schaeffer; Endre Mikus; E Boronkay; J Gyürky; Jean-Marc Herbert; Marc Pascal
Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
Arzneimittel-Forschung 1999;49(8):685-93.
1999: Zoltan Kapui; J Bence; E Boronkay; Endre Mikus; K Urbán Szabó; A Baranyi; Péter Arányi
Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Neurobiology (Budapest, Hungary) 1999;7(1):71-3.
1998: Zoltan Kapui; Endre Mikus; J Bence; K Gerber; K Boér; D Korbonits; A Borsodi; Péter Arányi
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl) methyl]. 3rd communication: examinations on opioid mechanisms and physical drug dependence.
Arzneimittel-Forschung 1998;48(12):1147-55.
1997: Endre Mikus; Zoltan Kapui; D Korbonits; K Boér; E Boronkay; J Gyürky; J Révész; F Lacheretz; Marc Pascal; Péter Arányi
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 2nd communication: investigations on theophylline-like activities.
Arzneimittel-Forschung 1997;47(12):1358-63.
1997: Endre Mikus; J Révész; E Minker; D Korbonits; V Saano; Marc Pascal; Péter Arányi
Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 1st communication: in vivo demonstration of the effects on animal models of cough and of mucociliary clearance.
Arzneimittel-Forschung 1997;47(4):395-400.
1987: P S Körmöczy; C Vértesi; Endre Mikus; L Tardos; G Kovács
Cardioprotective effect of prostacyclin and 7-oxo-PGI2 in rats against chronic isoproterenol damage.
Prostaglandins 1987;33(4):505-16.